Thelansis

Retinoblastoma Market Outlook Thelansis’s “Retinoblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinoblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do in...

Retinoblastoma Market Outlook Thelansis’s “Retinoblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinoblastoma     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Retinoblastoma Overview Retinoblastoma, although rare, stands as the predominant ocular neoplasm in childhood. It emerges as a malignant proliferation originating from the developing retina, typically manifesting before age five. This tumor arises from cells harboring cancer-predisposing variants in both alleles of the RB1 gene. Its presentation may be unifocal or multifocal. Approximately 60% of cases present as unilateral retinoblastoma, with a m...

  Theriva Biologics, a clinical-stage biotech company developing cancer therapeutics, announced that the European Commission has adopted the EMA’s recommendation to grant orphan medicinal product designation to VCN-01. VCN-01, a systemic, selective, stroma-degrading oncolytic adenovirus for treating retinoblastoma. This designation follows previous recognitions by the U.S. Food and Drug Administration (FDA), which has granted both orphan drug designation and rare pediatric disease designation to VCN-01 for retinoblastoma. Publish Date: 16-10-2024   Source: Theriva Biologics Retinoblastoma, although rare, stands as the predominant ocular neoplasm in childhood. It emerges as a malignant proliferation originating from the developing retina, typically manifesting before age five. This tumor arises from cells harboring cancer-predisposing variants in both alleles of the RB1 gene. Its presentation may be unifocal or multifocal. Approximately 60% of cases present as unilateral...

Retinoblastoma, although rare, stands as the predominant ocular neoplasm in childhood. It emerges as a malignant proliferation originating from the developing retina, typically manifesting before age five. This tumor arises from cells harboring cancer-predisposing variants in both alleles of the RB1 gene. Its presentation may be unifocal or multifocal. Approximately 60% of cases present as unilateral retinoblastoma, with a mean diagnosis age of 24 months, while around 40% present with bilateral involvement, typically diagnosed at 15 months of age. Heritable retinoblastoma follows an autosomal dominant pattern, increasing susceptibility to the disease and predisposing affected individuals to non-ocular tumors. The prognosis of localized disease is favorable for long-term survival, in stark contrast to metastatic retinoblastoma, characterized by aggressive behavior and dismal outcomes. The genetic underpinning of retinoblastoma is well-established, with evidence suggesting autosomal domi...

  Retinoblastoma is a rare tumor but is the most common eye tumor of childhood. Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors. When it remains localized to the eye, the prognosis is excellent for long-term survival, whereas metastatic retinoblastoma is an aggressive malignant neoplasm with poor survival rates. Through this experience, retinoblastoma has been found to have a strong genetic component. So...

  Retinoblastoma is a rare tumor but is childhood’s most common eye tumor. Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors. The prognosis is excellent for long-term survival when it remains localized to the eye, whereas metastatic retinoblastoma is an aggressive malignant neoplasm with poor survival rates. Through this experience, retinoblastoma has been found to have a vital genetic component. Some case...